Education
About Us
Working with TipRanks
Follow Us
Lexicon Pharmaceuticals (LXRX)
NASDAQ:LXRX
Earnings Data
Report Date
Jul 31, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
-0.08Last Year’s EPS
-0.17Same Quarter Last Year
Moderate Buy
Based on 3 Analysts Ratings
Earnings Call Summary
Earnings Call Date:May 13, 2025
|% Change Since: 17.46%
|Next Earnings Date:Jul 31, 2025
Earnings Call Sentiment|Positive
The call presented a generally positive outlook for Lexicon Pharmaceuticals, with significant achievements such as the Novo Nordisk partnership and successful Phase 2B results for pilavapadin. Financial restructuring has been effective, although there are ongoing costs associated with R&D. The sentiment is overall positive with strong strategic positioning and reduced losses.Company Guidance
During the Lexicon Pharmaceuticals first quarter 2025 financial results conference call, the company provided several forward-looking statements and updates on their drug programs. Key metrics included a license agreement with Novo Nordisk for LX9851, with Lexicon eligible for up to $1 billion in milestone payments and $75 million in upfront and near-term payments, of which $45 million was already received. The company also reported a net loss of $25.3 million for the quarter, down from $48.4 million the previous year, and ended the quarter with $194.8 million in cash and short-term investments. Operating expenses for 2025 are expected to be between $135 million and $145 million. Progress was highlighted in their pilavapadin and sotagliflozin programs, with a focus on advancing Phase 3 studies and ongoing strategic partnerships to expand their global footprint.Exclusive License Agreement with Novo Nordisk
Lexicon announced an exclusive license agreement with Novo Nordisk for LX9851, potentially worth up to $1 billion, including an upfront payment of $45 million received in April 2025.
Phase 2B Study Success for Pilavapadin
Lexicon identified a well-tolerated dose for pilavapadin in their Phase 2B study, demonstrating clear evidence of effect for Phase 3 studies.
Improved Financial Position
Lexicon improved their balance sheet by reducing operating costs, using the upfront payment from Novo Nordisk to reduce debt, and ending the quarter with $194.8 million in cash and short-term investments.
Strong Progress with Sotagliflozin
Lexicon remains on track with enrollment in the SONATA HCM study of sotagliflozin, with confidence in its potential for both obstructive and non-obstructive HCM.
Successful Restructuring and Cost Reduction
Selling, general and administrative expenses decreased significantly to $11.6 million from $32.1 million in Q1 2024 due to strategic repositioning.
LXRX Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
LXRX Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 13, 2025 | $0.63 | $0.53 | -15.87% |
Mar 06, 2025 | $0.37 | $0.39 | +5.41% |
Nov 12, 2024 | $1.19 | $1.09 | -8.40% |
Aug 01, 2024 | $2.02 | $1.70 | -15.84% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Lexicon Pharmaceuticals (LXRX) report earnings?
Lexicon Pharmaceuticals (LXRX) is schdueled to report earning on Jul 31, 2025, TBA Not Confirmed.
What is Lexicon Pharmaceuticals (LXRX) earnings time?
Lexicon Pharmaceuticals (LXRX) earnings time is at Jul 31, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is LXRX EPS forecast?
LXRX EPS forecast for the fiscal quarter 2025 (Q2) is -0.08.